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1 Introduction
 Preeclampsia (PE) is major cause of maternal 
mortality and morbidity that affects 5% to 8% of 
pregnancies 1）. It is a multisystem disorder that is specific 
to pregnancy, and it can be defined as new onset 
hypertension, proteinuria, and edema after 20 weeks' 
gestation 2）. Many causes of PE have been proposed 
although the pathological mechanisms underlying the 
disorder are still not fully understood 3），4）. However, 
there are two recognized clinical subtypes of PE, which 
are based on the time of onset or recognition of disease 5）; 
early onset PE occurs before 33 weeks' gestation, 
whereas late onset PE occurs after 34 weeks, with the 
former being responsible for much of the high maternal 
and fetal mortality and morbidity.
 The two-stage model is a popular hypothesis for 
the mechanism underlying PE. It proposes that reduced 
placental perfusion (Stage 1) produces factors that 
lead to the clinical manifestations of PE (Stage 2). The 
main pathological cause of ischemia-reperfusion of 
the placenta is deficient conversion of spiral arteries. In 
turn, oxidative stress by hypoperfusion induces the 
release of proinflammatory factors into the maternal 
circulation, which causes endothelial cell dysfunction 
and, ultimately, the characteristic pathological changes 
of PE 6），7）. It is reported these mechanism is a main 
feature of early onset disease 8）.
 There are complex interactions and close links 
between endoplasmic reticulum (ER) stress and oxidative 
stress 9），10），11）. The ER serves multiple functions, including 
the synthesis, post-translational modification, and 
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trafficking of membrane and secreted proteins. 
Overloading of the ER with these proteins or perturbation 
of its homeostasis through misfolding or abnormal 
glycosylation can provoke ER stress known as a condition 
of accumulation of misfolded or unfolded proteins in the 
lumen 10）. This then activates the signaling pathways 
of the unfolded protein response (UPR), which seeks to 
restore ER function by attenuating protein translation, 
increasing folding capacity, and facilitating the 
degradation of misfolded proteins 11），12），13）. Placental ER 
stress has recently been recognized as central to the 
pathophysiology of early onset PE 14），15）.
 PE has been postulated to involve an imbalance 
between angiogenic and anti-angiogenic factors. This 
includes the pro-angiogenic placental growth factor (PlGF), 
a homodimeric glycoprotein with significant homology 
to vascular endothelial growth factor A (VEGF-A) 
that was first identified in the human placenta 16）. PlGF 
is known to bind to VEGF receptor 1 (VEGFR1), which 
is also known as fms-like tyrosine kinase-1 receptor (Flt-
1) 17）, and more recent data indicate that concentrations 
of PlGF are reduced in the circulation of women with 
fetal growth restriction and PE 18），19）, particularly 
when early onset. Anti-angiogenic factors, including 
soluble Flt-1 (sFlt-1) that binds VEGF-A and soluble 
endoglin (sENG), are increased in the maternal 
circulation before early onset PE develops 19），20）. 
However, the molecular mechanisms leading to the down-
regulation of PlGF in the pathogenesis of PE are not 
known.
 We previously reported that PlGF expression in 
early onset PE was regulated by ER stress provoked 
by placental ischemia 14）, and the main pathway to 
regulate PlGF was protein kinase R-like endoplasmic 
reticulum kinase (PERK)-eukaryotic initiation factor 2 
subunit α(eIF2α)-activating transcription factor 4 (ATF4) 
pathway 21）. PE involves genetic and environmental 
factors in its pathogenesis and pathophysiology, and 
fetal and placental delivery has long been considered 
the only certain way to stop disease progression 22）. 
However, metformin and pravastatin have recently 
been shown to be beneficial in preventing PE 23），24） and, 
although the underlying molecular mechanisms are 
unclear, they appear to prevent ER stress 25），26）. To 
examine whether these agents could prevent PE, we 
therefore investigated if they effectively suppressed 
ER stress, via PERK pathway, and increased PlGF 
expression in trophoblast-like cells.
2 Materials and Methods
2.1 Materials used
 The culture media, phosphate buffered saline, and 
supplements were purchased from Life Technologies, 
CA, USA. Metformin was obtained from Enzo Life 
Science, NY, USA. Pravastatin and thapsigargin were 
purchased from SIGMA－ALDRICH CORP., MO, USA. 
The radioimmunoprecipitation assay (RIPA) buffer and 
protease inhibitor cocktail were purchased from Wako 
Pure Chemical Industries, Osaka, Japan.
2.2 Cell culture
 Human choriocarcinoma BeWo cells were obtained 
from RIKEN Cell Bank, Ibaraki, Japan, and were 
cultured in Roswell Park Memorial Institute medium 
(RPMI) 1640 medium supplemented with 5% heat-
inactivated fetal bovine serum (HI-FBS), penicillin (100 
U/mL), and streptomycin (100 µg/mL) at 37 ℃ in a 
CO2 atmosphere.
2.3 Western blot analysis
 Cells were washed twice with phosphate buffered 
saline, harvested in 200 µL of lysis buffer by scraping, 
and briefly vortexed. The lysis buffer contained RIPA 
buffer and protease inhibitor cocktail. After pipetting 
up and down approximately 30 times, cells were 
maintained on ice until use and then centrifuged at 
14,000 × g for 20 min. The supernatant was kept at 
－80 ℃ until analysis.
 A Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific, DE, USA) was used to determine protein 
concentrations using 25 µL of cell lysate. Equivalent 
amounts of protein were electrophoresed on 12% 
sodium dodecyl sulfate polyacrylamide gels (Bio-Rad 
Laboratories, Hercules, CA, USA) and blotted onto 
a polyvinylidene difluoride membrane by iBlot Gel 
Transfer Device (Thermo Fisher Scientific).
 Primary and secondary antibodies were applied 
for 1.5 h at room temperature. Primary antibodies were 
as follows: rabbit anti-p-eIF2α (#3597, 1:5,000 dilution), 
rabbit anti-ATF-4 (#11815, 1:1,000 dilution), and mouse 
anti-β-actin (#3700, 1:5,000 dilution) from Cell Signaling 
technology, MA, USA; and mouse anti-PlGF (sc-
57402, 1:1,000 dilution) from Santa Cruz Biotechnology, 
TX, USA. The secondary antibodies, swine anti-rabbit 
IgG-HRP (P0217) and rabbit anti-mouse IgG-HRP 
(P0260), were obtained from Agilent technologies, CA, 
USA. Horseradish peroxidase (HRP) activity was 
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detected by chemiluminescence (ECL prime) (GE 
Healthcare, Buckinghamshire, England UK) using an 
Image Quant LAS 500 (GE Healthcare). The intensities 
of bands representing phosphorylated and total kinase 
forms were analyzed by Image Quant TL (GE Healthcare).
2.4 Quantitative real - time reverse transcription - 
polymerase chain reaction (RT - qPCR)
 RT - qPCR was performed as follows. Total RNA 
was isolated using RNeasy Mini Kits (Qiagen, Hilden, 
Germany) according to the manufacturer's protocol. 
RNA samples were stored at －80 ℃ . Then, 1 μg total 
RNA was transcribed into complementary DNA using 
Oligo (dt) 12-18 primer, 10 mM dNTP Mix, RNase out 
Recombinant Ribonuclease Inhibitor, and Super Script 
II Reverse Transcriptase (Thermo Fisher Scientific) 
according to the manufacturer's protocol, using a 
TAKARA PCR Thermal Cycler Dice Touch (TAKARA 
Bio USA, CA, USA). The mRNA expression was then 
determined using SYBR Green (Bio-Rad Laboratories). 
The Step One Real-Time PCR System (Thermo Fisher 
Scientific) used the following conditions: 95 ℃ for 3 
min, 95 ℃ for 15 s, and 60 ℃ for 1 min (40 cycles). Details 
of the primer sequences (SIGMA－ALDRICH CORP.) 
are shown in Table 1. All data were normalized to 
TATA - box binding protein (TBP) as the internal control 
gene, and calibrated against the average cycle threshold 
of the control samples. Results were expressed as 
fold change from control.
2.5 Statistical analysis
 Differences were tested using both the Mann-
Whitney U test and the two-tailed Student's t-test. 
Statistical analysis was performed using GraphPad 
Prism 6.0 (GraphPad Software, La Jolla, CA, USA), 
with p < 0.05 considered significant.
3 Results
3.1 Thapsigargin positively regulates ATF4 mRNA and 
negatively regulates PlGF mRNA in trophoblast-
like cell lines
 The human choriocarcinoma cell line BeWo and 
the chemical ER stress inducer thapsigargin, an 
inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase, 
were used for in vitro studies to confirm whether ER 
stress negatively regulated PlGF mRNA transcription. 
We previously reported the negative correlation of 
ATF4 and PlGF mRNA transcription in BeWo cells 
[21], with the former being a transcription factor of 
ER stress in the PERK signaling pathway. Thus, we 
proposed that PlGF expression may be regulated by the 
PERK pathway. The results presented Fig 1 indicate 
Table 1. Primer sequences used for quantitative real - time RT - PCR.
Gene Forward Sequence 5'–3' Reverse Sequence 5'–3' Size
PlGF TGATCTCCCCTCACACTTTGC CACCTTGGCCGGAAAGAA 62 bp
ATF4 GACGGAGCGCTTTCCTCTT TCCACAAAATGGACGCTCAC 69 bp
TBP GGGTTTTCCAGCTAAGTTCTT CTGTAGATTAAACCAGGAAAT 137 bp
(A) (B)
Figure 1. ER stress induced marked down-regulation of PlGF mRNA in trophoblastic-like cells.
 BeWo cells were cultured for 24 h with thapsigargin in normal growth medium without serum. RT - qPCR was used 
to measure PlGF and ATF4 mRNA levels. (A) After treatment with thapsigargin, PlGF mRNA was significantly reduced; 
data are presented as mean ± SEM, n = 5; *** p < 0.001. (B) The expression of ATF4 mRNA was induced in 
trophoblastic-like cells under the same conditions; data are presented as mean ± SEM, n = 3; ** p < 0.01. The primary 
data consisted these results was supporting figure 1-(A) and 1-(B) contained in supporting information.
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that thapsigargin negatively regulated PlGF mRNA 
transcription and positively regulated ATF4 mRNA 
transcription, with a significant difference between 
the control and thapsigargin groups. There was also no 
dose-dependent effect of thapsigargin for increasing 
ATF4 and decreasing PlGF levels.
3.2 PlGF mRNA was restored by metformin during ER 
stress
 Fig 2(A) indicates that PlGF mRNA expression 
was increased by metformin administration when given 
alone, with a significant difference for metformin 
concentrations up to 3 mM. To investigate whether the 
expression of PlGF mRNA was increased by metformin 
under ER stress, we administered metformin and 
thapsigargin together. Fig 2(B) shows that metformin 
increased PlGF mRNA expression under ER stress 
and that metformin plus thapsigargin also increased 
PlGF mRNA expression compared with thapsigargin 
alone (and did so in a dose-dependent manner). The 
significant difference was also shown at doses of 
metformin up to 3 mM, which almost fully restored 
PlGF mRNA levels to those of the control group. 
3.3 PlGF was restored by metformin during ER stress
 To verify the sequence results of RT - qPCR, we 
performed western blot analyses and investigated whether 
metformin inhibited the UPR pathway, and the PERK 
pathway in particular. Fig 3(A) shows that levels of 
phosphorylated eIF2α (p-eIF2α) were increased under 
treatment with thapsigargin alone, whereas Fig 3(B) 
shows that ATF4 levels were also increased. This is 
consistent with our understanding that eIF2α 
phosphorylation is known to mediate increased 
transcription and translation of ATF4 in the PERK 
pathway. In Fig 3(C), PlGF is shown to have been 
reduced under treatment with thapsigargin alone. 
These results show that ER stress activates the PERK-
eIF2α-ATF4 signaling pathway and thereby reduces 
PlGF protein expression in trophoblast-like cells. In 
addition, Fig 3(A) and Fig 3(B) show that the expressions 
of p-eIF2α and ATF4 were reduced under treatment 
with thapsigargin and metformin when compared to 
treatment with thapsigargin alone. Fig 3(C) also shows 
that metformin restored or increased PlGF expression 
under ER stress. Thus, metformin can restore PlGF 
protein expression and either directly or indirectly 
inhibit the PERK pathway under ER stress.
3.4 PlGF expression was restored by pravastatin during 
ER stress
 Western blot was performed to investigate whether 
pravastatin inhibited the PERK pathway and restored 
PlGF expression. Fig 4(A) shows that ATF4 was increased 
under treatment with thapsigargin alone, but that 
its expression was attenuated under treatment with 
thapsigargin plus pravastatin. In Fig 4(B), PlGF is shown 
to be reduced under treatment with thapsigargin alone. 
By contrast, PlGF expression is slightly increased under 
treatment with thapsigargin plus pravastatin compared 
(A) (B)
Figure 2. Metformin induced PlGF mRNA under ER stress in trophoblastic-like cells.
 RT - qPCR was used to measure PlGF expression. (A) There was a dose-dependent increase in PlGF mRNA during treatment 
with metformin alone. BeWo cells were cultured in metformin with normal growth medium without serum for 24 h; data 
are presented as mean ± SEM, n = 4; * p < 0.05. (B) Metformin restored PlGF mRNA expression under ER stress. BeWo 
cells were treated for 24 h with metformin and thapsigargin. Both drugs were given together; data are presented as mean ± 
SEM, n = 4; * p < 0.05. The primary data consisted these results was supporting figure 2-(A) and 2-(B) contained in 
supporting information.
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with thapsigargin alone. Thus, pravastatin also restored 
PlGF protein expression, directly or indirectly inhibiting 
the PERK pathway under ER stress.
4 Discussion
 Various approaches have been investigated to 
identify the pathogenesis of PE in the first trimester, 
including the use of pregnancy-associated plasma 
protein (PAPP-A), human chorionic gonadotropin (hCG), 
placental protein 13 (PP13), and uterine artery Doppler, 
or some combination of all these methods 27），28）. The 
reduction of maternal circulating PlGF concentrations 
is another of these predictive factors 29）, and we have 
previously reported that the expression of PlGF mRNA 
is reduced more in the placentas of early onset PE 
compared with those of either late onset PE or age-
matched controls. We therefore proposed that placental 
ER stress could be a regulatory factor in PlGF reduction, 
though the mechanism was unclear 21）.
 ER stress leads to activation of the UPR, which 
consists of three signaling pathways: PERK, activating 
transcription factor 6 (ATF6), and inositol-requiring 1 
(IRE1). Activation of the PERK signaling pathway 
causes the phosphorylation of eIF2α, and p-eIF2α 
induces the expression of ATF4. This PERK-eIF2α
-ATF4 pathway attenuates non-essential protein 
synthesis and increases antioxidant defense systems. 
(A)
p-eIF2α
38kDa
Β-actin
45kDa
Metformin (mM) 0 0.3 0 0.3 0.3 0.3
Tg (µM) 0 0 3 0.1 1 3
(B)
ATF-4
49kDa
Β-actin
45kDa
Tg (µM) 0 0.3 0 0.3 0.3 0.3
Metformin (mM) 0 0 3 0.1 1 3
(C)
PlGF
18kDa
Β-actin
45kDa
Tg (µM) 0 0.3 0 0.3 0.3 0.3
Metformin (mM) 0 0 3 0.1 1 3
Figure 3. Western blot analyses of p-eIF2α , ATF4, and PlGF 
in trophoblast-like cells.
 BeWo cells were cultured in normal growth medium 
without serum and were treated for 24 h with either 
thapsigargin alone, metformin alone, or thapsigargin 
plus metformin (administered together). (A and B) 
Levels of p-eIF2α and ATF4 were increased during 
treatment with thapsigargin alone, but were reduced 
under treatment with thapsigargin plus metformin 
when compared with thapsigargin alone. When both 
drugs were given, the reduction was greater for 3 
mM than for 0.1 mM metformin. (C) PlGF was clearly 
increased under treatment with thapsigargin and 
metformin compared with thapsigargin alone. Each 
figure panels were comprised of same blot fragment 
spliced because aimed bands were non-adjacent. Each 
original blots panels were supporting figure 3-(A), 
3-(B), and 3-(C) in supporting information. Splicing 
lines were indicated with vertical lines.
(A)
ATF-4
49kDa
Β-actin
45kDa
Tg (µM) 0 0.3 0 0.3 0.3 0.3
Metformin (mM) 0 0 50 5 30 50
(B)
PlGF
18kDa
Β-actin
45kDa
Tg (µM) 0 0.3 0 0.3 0.3 0.3
Metformin (mM) 0 0 50 5 30 50
Figure 4. Western blot analyses of ATF4 and PlGF in trophoblast-
like cells.
 BeWo cells were cultured in normal growth medium 
without serum and treated for 24 h with either 
thapsigargin alone, pravastatin alone, or thapsigargin 
plus pravastatin (administered together). (A) ATF4 
levels increased under treatment with thapsigargin 
alone, but, by comparison, were reduced under treatment 
with thapsigargin plus metformin. In particular, ATF4 
was attenuated by 0.3 µM thapsigargin with either 
30 µM or 50 µM pravastatin. (B) PlGF was slightly 
increased during thapsigargin and metformin treatment 
compared with thapsigargin alone. Each figure panels 
were comprised of same blot fragment spliced because 
aimed bands were non-adjacent. Each original blots 
panels were supporting figure 4-(A) and 4-(B) in 
supporting information. Splicing lines were indicated 
with vertical lines.
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ATF6 released from glucose-regulated protein 
(GRP78) then upregulates ER chaperone genes to 
increase folding capacity. Activation of IRE1 leads to 
splicing of XBP1 pre-mRNA. This results in increased 
phospholipid biosynthesis and breakdown of misfolded 
proteins. IRE1 also activates proinf lammatory 
pathways through its kinase domain. But, if these 
attempts fail, an apoptotic pathway is activated to 
eliminate the damaged cells 30），31），32）. Previously, we 
demonstrated the negative correlation between ATF4 
and PlGF expression in the placentas of women 
suffering from early onset PE. In the present study, 
our results were confirmed in trophoblast-like cells 
given chemical inducers of ER stress. These results 
support our experimental hypothesis, indicating that 
an ER stress signaling pathway, PERK-eIF2α-ATF4, 
regulates PlGF expression in the placenta of early 
onset PE 21）.
 Definitive treatment for PE is delivery of fetus 
and placenta 33），34）, but no preventive or therapeutic 
medications are readily available. However, based on 
our previous research 21） and that of others, we were 
interested in the possibility of using metformin and 
pravastatin for their effects as suppressors of ER 
stress.
 Metformin is a first-line agent in the treatment of 
type 2 diabetes mellitus 35） and metabolic syndrome 36）. 
It is safe for use in pregnancy 37） and is useful when 
treating gestational diabetes mellitus 38），39）. A widely 
accepted model for the anti-hyperglycemic action of 
metformin is that its inhibition of the mitochondrial 
respiratory chain (complex I) results in suppression of 
hepatic gluconeogenesis. This inhibition of mitochondrial 
function, which is provoked by metformin and other 
mitochondrial inhibitors, results in activation of the 
5' adenosine monophosphate-activated protein kinase 
(AMPK) pathway. This, in turn, appears to be the key 
action of metformin, primarily because the effect has 
close links with the inactivation of pathological conditions 
such as mammalian target of rapamycin (mTOR), ER 
stress, oxidative stress, and hypoxia 40），41）. Based on 
these new findings, some researchers have attempted 
to describe the mechanisms by which the activation of 
AMPK signaling by metformin inactivates pathologic 
pathways such as ER stress 42），43）.
 Recently, for example, metformin was reported 
to reduce sFlt-1 and sENG by inhibiting complex I in 
mitochondria. It was also shown to improve endothelial 
dysfunction by reducing vascular cell adhesion molecule 1, 
an inflammatory adhesion molecule induced by tumor 
necrosis factor α (TNFα) and upregulated by endothelial 
dysfunction 44）. Both sFlt-1 and sENG are anti-angiogenic 
proteins that are increased in the circulations of women 
with PE and may cause endothelial dysfunction and PE 
injury. As stated, PE is a two-stage disease of imbalance 
between angiogenic and anti-angiogenic factors. 
Logically, if metformin increases the pro-angiogenic 
PlGF and decreases the anti-angiogenic sFlt-1 and 
sENG, endothelial dysfunction should be impaired and 
angiogenesis should be enhanced.
 Also known as hydroxymethylglutaryl (HMG)-
CoA reductase inhibitors, statins are a major drug 
class used to treat dyslipidemia. Pravastatin is a 
first-generation, hydrophilic statin. Cohort studies 
have shown that, while hydrophobic statins increase the 
risk of fetal malformation, hydrophilic statins do 
not; moreover, pravastatin has an established safety 
profile among pregnant woman 45）. There has also been 
recent interest in the use of statins to treat PE 
based on evidence of their vasoprotective effects and 
ability to impair endothelial dysfunction in other 
disorders. Notably, we were interested in the reports 
that pravastatin decreased sFlt-1 and sENG, and 
upregulated PlGF and VEGF in PE-like animal models 46）, 
and that the reduction of sFlt-1 by statins was directly 
mediated thorough HMG-CoA reductase 47）. Although 
the mechanisms through which statins reverse the 
angiogenic and anti-angiogenic imbalance are not 
clearly understood, we speculate that it may involve 
inactivation of the ER stress pathway through 
inhibition of HMG-CoA reductase. Pravastatin may 
also be both preventive and therapeutic, similarly to 
metformin.
 There is no evidence on whether metformin and 
pravastatin suppress ER stress in trophoblast-like 
cells, though there are some reports that these drugs 
decrease anti-angiogenic factors 44），46）. This is the first 
report to examine the effect of these drugs on placental 
ER stress in choriocarcinoma cells. Of note, we showed 
that metformin or pravastatin could attenuate the PERK 
pathway to restore PlGF expression in trophoblast-
like cells under ER stress, supporting our previous 
report that placental ER stress downregulated the 
expression of PlGF via the PERK pathway in placentas 
with PE. Metformin and pravastatin offer potential 
as preventive or treatment agents for PE, and may 
act by correction of the low pro-angiogenic factors in 
maternal circulations when PE develops.
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 Unfortunately, despite this promise, there remain 
many problems that need to be addressed in the future. 
For example, we must investigate the mechanisms 
of how metformin and pravastatin suppress ER stress 
in trophoblast-like cells. Although we did demonstrate 
that metformin and pravastatin inhibited placental 
ER stress, we do not know whether this effect was 
direct or indirect. A putative mechanism of metformin is 
that activation of AMPK by mitochondrial inhibition 
both triggers, and is a key action of, attenuated ER stress 
in trophoblast-like cells. In recent reports suggesting 
inhibition of ER stress by metformin, it has been 
proposed that AMPK activation by metformin may 
trigger the subsequent cascade. Although the downstream 
effects of ER stress suppression remain unknown, 
various putative hypotheses have been verified in other 
fields that may offer insights into the mechanisms of 
metformin in placentas in PE. A metabolic function of 
AMPK is lipid metabolism, wherein it inhibits cholesterol 
synthesis by inducing the inhibitory phosphorylation 
of HMG-CoA reductase 48）. Therefore, inhibition of HMG-
CoA reductase may play an important role in suppressing 
ER stress. Further research is needed into whether our 
results are reproducible in vivo, using preeclamptic 
placental villous explants.
 To conclude, we previously demonstrated that 
placental ER stress via the PERK signaling pathway 
could result in PlGF levels being reduced in early onset 
PE. In this study, we add to this data by showing that 
metformin and pravastatin attenuated ATF4 levels, 
a regulating factor of the PERK pathway, and restored 
PlGF levels in trophoblast-like cells. These findings 
support the need for further studies to elucidate the 
mechanisms underlying these processes. In the meantime, 
we believe that metformin and pravastatin continue to 
show promise as therapeutic drugs for use in PE.
 
Acknowledgements
 This research was conducted at the Sapporo Medical 
University, Japan. The authors thank the staff of the 
department of Obstetrics for technical supports. 
Disclosure
 Research was supported by Japan Society for 
the Promotion of Science KAKENHI Grant Number 
15K20153.
References
1） Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. 
WHO analysis of causes of maternal death: a systematic 
review. Lancet 2006; 367: 1066-1074.
2） Fu J, Zhao L, Wang L, Zhu X. Expression of markers of 
endoplasmic reticulum stress-induced apoptosis in the 
placenta of women with early and late onset severe pre-
eclampsia. Taiwan J Obstet Gynecol 2015; 54: 19-23.
3） Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers 
soluble fms-like tyrosine kinase-1 and placental growth 
factor: current knowledge, clinical implocations and future 
application. Eur J Obstet Gynecol Reprod Biol 2010; 151: 
122-129.
4） Redman CW, Sargent IL. Latest advances in understanding 
preeclampsia. Science 2005; 308: 1592-1594.
5） Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor 
RN, Powers RW Charnock-Jones DS, Redman CW. 
Redefining preeclampsia using placenta-derived biomarkers. 
Hypertension 2013; 61: 932-942.
6） Roberts JM, Hubel CA. Is oxidative stress the link in the 
two-stage model of pre-eclampsia? Lancet 1999; 354: 788-
789.
7.） Redman CWG, Sargent IL. Placental debris, oxidative stress 
and pre-eclampsia. Placenta 2000; 21: 597-602.
8） Von Dadelszen P, Magee LA, Roberts JM. Subclassification of 
preeclampsia. Hypertens Pregnancy 2003; 22: 143-148.
9） Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, 
Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, 
Hettmann T, Leiden JM, Ron D. An integrated stress 
response regulates amino acid metabolism and resistance to 
oxidative stress. Mol Cell 2003; 11: 619-633.
10） Xue X, Piao JH, Nakajima A, Sakon-Komazawa S, Kojima 
Y, Mori K, Yagita H, Okumura K, Harding H, Nakano H. 
Tumor necrosis factor alpha (TNF alpha) induces the unfolded 
protein response (UPR) in a reactive oxygen species (ROS)-
dependent fashion, and the UPR counteracts ROS accumulation 
by TNF alpha. J Biol Chem 2005; 280: 33917-33925.
11） Cullinan SB, Diehl JA. Coordination of ER and oxidative stress 
signaling: the PERK/Nrf2 signaling pathway. Int J Biochem 
Cell Biol 2006; 38: 317-332.
12） Schroder M, Kaufman RJ. ER stress and the unfolded protein 
response. Mutat Res 2005; 569: 29-63.
13） Yoshida H. ER stress and diseases. FEBS J 2007; 274: 630-658.
14） Yung HW, Atkinson D, Campion-Smith T, Olovsson M, 
Charnock-Jones DS, Burton GJ. Differential activation of 
placental unfolded protein response pathways implies 
heterogeneity in causation of early- and late-onset pre-eclampsia. 
J Pathol 2014; 234: 262-276. 
15） Ron D, Walter P. Signal integration in the endoplasmic 
reticulum unfolded protein response. Nat Rev Mol Cell Biol 
2007; 8: 519-529.
16） Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. 
Isolation of a human placenta cDNA coding for a protein related 
to the vascular permeability factor. Proc Natl Acad Sci U S 
A 1991; 88: 9267-9271.
17） Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta 
growth factor. Potentiation of vascular endothelial growth 
82 Masahiro Suzuki et al.
factor bioactivity, in vitro and in vivo, and high affinity 
binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 
269: 25646-25654.
18） Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg 
CS, Spencer K. First-trimester placental growth factor as a 
marker for hypertensive disorders and SGA. Prenet Diagn 
2010; 30: 565-570. 
19） Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, 
Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai 
BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic 
factors and the risk of preeclampsia. N Engl J Med 2004; 350: 
672-683.
20） Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, 
Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi 
SA; CPEP Study Group. Soluble endoglin and other circulating 
antiangiogenic factors in preeclampsia. N Engl J Med 2006; 
355: 992-1005.
21） Mizuuchi M, Cindrova-Davies T, Olovsson M, Charnock-Jones 
DS, Burton GJ, Yung HW. Placental endoplasmic reticulum 
stress negatively regulates transcriotion of placental growth 
factor via ATF4 and ATF6β: implications for the pathophysiology 
of human pregnancy complications. J Pathol 2016; 238: 550-
561. 
22） Romero R, Chaiworapongsa T. Preeclampsia: a link between 
trophoblast dysregulation and an antiangiogenic state. J Clin 
Invest 2013; 123: 2775-2777.
23） Syngelaki A, Nicolades KH, Balani J, Hyer S, Akolekar R, 
Pastides A, Shehata H. Metformin versus Placebo in Obese 
Pregnant Women without Diabetes Mellitus. N Engl J Med 
2016; 374: 434-443.
24） Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, 
Regal JF, Gilbert JS. Pravastatin attenuates hypertension, 
oxidative stress, and angiogenic imbalance in rat model of 
placental ischemia-induced hypertension. Hypertension 2013; 
61: 1103-1110.
25） Kim H, Moon SY, Kim JS, Baek CH, Kim M, Min JY, Lee 
SK. Activation of AMP-activated protein kinase inhibits ER 
stress and renal fibrosis. Am J Physiol Renal Physiol 2015; 308: 
F226-236. 
26） Kojanian H, Szafran-Swietlik A, Onstead-Haas LM, Haas MJ, 
Mooradian AD. Statins prevent dextrose-induced endoplasmic 
reticulum stress and oxidative stress in endothelial and 
HepG2 Cells. Am J Ther 2016; 23: e1456-e1463. doi: 10.1097/
MJT.0000000000000073.
27） Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, 
Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, 
Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME. 
First-trimester maternal serum PAPP-A and free-beta subunit 
human chorionic gonadotropin concentrations and nuchal 
translucency are associated with obstetric complications: a 
population-based screening study (the FASTER Trial). Am 
J Obstet Gynecol 2004; 191: 1446-1451.
28） Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papantoniou 
N, Mesogitis S, Antsaklis A. Screening for pre-eclampsia and 
fetal growth restriction by uterine artery Doppler and PAPP-A 
at 11-14 weeks' gestation. An Ultrasound Obstet Gynecol 2007; 
29: 135-140.
29） Bian Z, Shixia C, Duan T. First-Trimester Maternal Serum 
Levels of sFLT1, PGF and ADMA Predict Preeclampsia. PloS 
One 2015; 10: e0124684. doi: 10.1371/journal.pone.0124684.
30） Yung HW, Korolchuk S, Tolkovsky AM Charnock-Jones 
DS, Burton GJ. Endoplasmic reticulum stress exacerbates 
ischemia-reperfusion-induced apotosis through attenuation 
of Akt protein synthesis in human choriocarcinoma cells. 
FASEB J 2007; 21: 872-884.
31） Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: 
cell life and death decisions. J Clin Invest 2005; 115: 2656-
2664.
32） Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum 
stress: disease relevance and therapeutic opportunities. Nat 
Rev Drug Discov 2008; 7: 1013-1030. 
33） Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, 
Romero R. Pre-eclampsia part 2: prediction, prevention and 
management. Nat Rev Nephrol 2014; 10: 531-540. 
34） Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive 
versus expectant management of severe preeclampsia at 28 
to 32 weeks' gestation: a randomized controlled trial. Am J 
Obstet Gynecol 1994; 171: 818-822.
35） Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman 
RR, Sherwin R Zinman B; American Diabetes Association; 
European Association for the Study of Diabetes. Medical 
management of hyperglycaemia in type 2 diabetes mellitus: 
a consensus algorithm for the initiation and adjustment of 
therapy. A consensus statement from the American Diabetes 
Association and the European Association for the Study of 
Diabetes. Diabetologia 2009; 52: 17-30. 
36） Kong W, Niu X, Zeng T, Lu M, Chen L. Impact of treatment 
with metformin on adipocytokines in patients with polycystic 
ovary syndrome: A meta-analysis. PLoS One 2015; 10: 
e0140565. doi: 10.1371/journal.pone.0140565.
37） Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin 
on pregnancy outcomes in women with polycystic ovary 
syndrome: A meta-analysis. Medicine (Baltimore) 2016; 95: 
e4526. doi: 10.1097/MD.0000000000004526.
38） Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG 
Trial Investigators. Metformin versus insulin for the treatment 
of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
39） Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco 
RP. Randomized trial of metformin vs insulin in the management 
of gestational diabetes. Am J Obstet Gynecol 2013; 209: 34.e1-
34.e7. doi: 10.1016/j.ajog.2013.03.022.
40） Rena G, Pearson ER, Sakamoto K. Molecular mechanism of 
action of metformin: old or new insights? Diabetologia 2013; 
56: 1898-1906.
41） Ravindran S, Kuruvilla V, Wilbur K, Munusamy S. 
Nephroprotective effects of metformin in diabetic nephropathy. 
J Cell Physiol 2017; 232: 731-742. 
42） Jung TW, Lee MW, Lee YJ, Kim SM. Metformin prevents 
endoplasmic reticulum stress – induced apotosis through 
AMPK-PI-3K-c-Jun NH2 pathway. Biochem Biophys Res 
83Metformin and statins attenuate ER stress
Commun 2012; 417: 147-152. 
43） Dong Y, Zhang M, Wang S, Liang B, Zhao Z, Liu C, Wu M, 
Choi HC, Lyons TJ, Zou MH. Activation of AMP- activated 
protein kinase inhibits oxidized LDL-triggered endoplasmic 
reticulum stress in vivo. Diabetes 2010; 59: 1386-1396. 
44） Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry 
LJ, Senadheera S, Illanes SE, Kaitu'u-Lino TJ, Tong S. 
Metformin as a prevention and treatment for preeclampsia: 
effects on soluble fms-like tyrosine kinase 1 and soluble 
endoglin secretion and endothelial dysfunction. Am J 
Obstet Gynecol 2016; 214: 356.e1-356.e15. doi: 10.1016/j.ajog. 
2015.12.019.
45） Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer 
P, Tsatsaris V. Statins and pregnancy: between supposed 
risks and theoretical benefits. Drugs 2012; 72: 773-788. 
46） Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, 
Tamayo E, Hankins GD, Saade GR, Costantine MM. 
Effects of pravastatin on angiogenic and placental hypoxic 
imbalance in a mouse model of preeclampsia. Reprod Sci 2014; 
21: 138-145.
47） Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, 
Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, 
Ahmed A. Negative regulation of soluble Flt-1 and soluble 
endoglin release by heme oxygenase-1. Circulation 2007; 
115: 1789-1797.
48） Carling D, Clarke PR, Zammit VA, Hardie DG. Purification 
and characterization of the AMP-activated protein kinase. 
Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy- 
3-methylglutaryl-CoA reductase kinase activities. Eur J 
Biochem 1989; 186: 129-136.
　　　　　　　　　　　　　　　　　　　　　　　　
別刷請求先：水内　将人
　　〒 060-8543　札幌市中央区南１条西 17 丁目
　　札幌医科大学医学部産婦人科学講座
　　TEL： 011-611-2111（内線 33730）
　　FAX：011-611-2299
　　E-mail：mizumasa@sapmed.ac.jp
84 Masahiro Suzuki et al.
ヒト絨毛癌細胞株 BeWoにおけるMetforminと Pravastatinの
小胞体ストレス応答と胎盤増殖因子に対する役割
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　妊娠高血圧腎症は血管新生因子の不均衡に起因して
いる．胎盤増殖因子は胎盤における血管新生因子のひ
とつであり，早発型妊娠高血圧腎症妊婦の血中や胎盤
では減少している．近年，メトホルミンやスタチン系
薬剤によって小胞体ストレス応答が抑制されることが
報告されている．我々は過去に小胞体ストレスにより
惹起される異常タンパク応答，その経路の一つである
PERK 経路を通して胎盤における胎盤増殖因子の発
現が抑制されることを報告した．これらの薬剤は胎盤
において小胞体ストレス応答を抑制し胎盤増殖因子の
発現を増加させることが予測できる．本研究の目的は
ヒト絨毛癌細胞株である BeWo において，これらの
薬剤が胎盤増殖因子や PERK 経路の調節因子である
activating transcription factor 4 (ATF4) の発現に
どのような影響を及ぼすかを調べることである．まず
小胞体ストレス応答誘導剤であるタプシガルギンを添
加した BeWo においては胎盤増殖因子のメッセン
ジャー RNAの発現が減少し，ATF4のメッセンジャー
RNA の発現が増加していることを確認した．しかし
タプシガルギンとメトホルミンを同時に添加した時，
胎盤増殖因子のメッセンジャー RNA の発現はメトホ
ルミンの濃度依存的に上昇することが観察された．ウ
エスタンブロット法を用いた観察においても小胞体スト
レス条件下の BeWo では ATF4 やもう一つの PERK
経路調節因子であるphosphorylated-eukaryotic initiation 
factor 2 subunit α (p-eIF2α) の発現は増加してい
るのに対し，胎盤増殖因子の発現は低下していること
が確認できた．逆に小胞体ストレス条件下においてメ
トホルミンを加えた場合は ATF4 や p-eIF2αの発現
は低下するのに対し胎盤増殖因子の発現は増加してい
ることが確認できた．またこれらの増減の程度は添加
するメトホルミンの濃度に依存していた．メトホルミ
ンをスタチン系薬剤であるプラバスタチンに置き換え，
同様にウエスタンブロット法にて各タンパクの発現を
観察した場合も同様の結果が得られた．結果としてメ
トホルミンとプラバスタチンは BeWo での小胞体ス
トレス応答を抑制し胎盤増殖因子の低下を防ぐことが
明らかとなり，これらの薬剤には妊娠高血圧腎症の発
症を予防する可能性が示唆された．今後その機序を解
明するためにさらなる研究が必要である．
